Inactive Instrument

STAR Pharmaceutical Limited Share Price

SRPT

SG1BB3000009

Latest news: STAR Pharmaceutical Limited

13/11/19	Star Pharmaceutical Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
06/10/19	Xu Zhi Bin, Executive Chairman of Board of STAR Pharmaceutical completed the acquisition of remaining 46.8% stake in STAR Pharmaceutical Limited from Li Tak Tai Leada and other shareholders.	CI
12/09/19	STAR Pharmaceutical Limited Announces Change of Registered Office Address	CI
04/08/19	Xu Zhi Bin, Executive Chairman of Board of STAR Pharmaceutical made an offer to acquire remaining 46.8% stake in STAR Pharmaceutical Limited from Li Tak Tai Leada and other shareholders for SGD 9.7 million.	CI
04/08/19	Xu Zhi Bin, Executive Chairman of Board of STAR Pharmaceutical acquired an additional 22.7% stake in STAR Pharmaceutical Limited from Wang Qi for SGD 1.5 million.	CI
31/07/19	Star Pharmaceutical Limited Reports Earnings Results for the Second Quarter Ended June 30, 2019	CI
31/07/19	Tranche Update on STAR Pharmaceutical Limited's Equity Buyback Plan announced on August 7, 2018.	CI
18/07/19	STAR Pharmaceutical Limited Provides Group Financial Guidance for the Half Year Ended 30 June 2019	CI
15/05/19	Star Pharmaceutical Limited Reports Earnings Results for the First Quarter Ended March 31, 2019	CI
15/05/19	Tranche Update on STAR Pharmaceutical Limited's Equity Buyback Plan announced on August 7, 2018.	CI
25/04/19	STAR Pharmaceutical Limited's Equity Buyback announced on August 7, 2018, has expired with 616,500 shares, representing 1.33% for SGD 0.09 million.	CI
01/03/19	STAR Pharmaceutical Limited Announces Board Changes	CI
27/02/19	Star Pharmaceutical Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	CI

More news

Press Releases: STAR Pharmaceutical Limited

05/12/19	Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director	PU
05/12/19	STAR Pharmaceutical : Mandatory Unconditional Cash Offer - Completion Of Compulsory Acquisition	PU
02/12/19	STAR Pharmaceutical : Mandatory Unconditional Cash Offer - Exercise Of Right Of Compulsory Acquisition	PU
29/10/19	STAR Pharmaceutical : Mandatory Unconditional Cash Offer - Despatch Of Documents Relating To Compulsory Acquisition	PU
07/10/19	STAR Pharmaceutical : Mandatory Unconditional Cash Offer - Close Of Offer	PU

More press releases

STAR Pharmaceutical Limited is an investment holding company. The principal activities of the subsidiaries are those relating to the development, manufacturing and trading of pharmaceutical products. The Company operates in the development, manufacturing and trading of pharmaceutical products segment. The Company and its subsidiaries are engaged in the manufacture and sale of both western and Traditional Chinese Medicine (TCM)-formulated prescription drugs. The Company's range of pharmaceutical products include antibiotics, cerebrovascular drugs and cardiovascular drugs, and other specialized drugs manufactured in-house in various dosages and administration forms from powder injections, lyophilized powder injections, liquid injections to tablets, capsules and granules. It has approximately 820 distributors to hospitals, clinics and pharmacies. The Company has a manufacturing facility based in Qionghai City, Hainan Province of People's Republic of China.

Employees

Sector

Pharmaceuticals

More about the company